/b_650_0224.jpg)
New Model Improves Understanding of How Medicines Reach the Brain
Researchers at UMC Utrecht and Amsterdam UMC have developed a novel laboratory model to mimic the human blood-brain barrier, offering a new way to study how pharmaceutical compounds reach cerebral tissue.
- A new laboratory model mimics the human blood-brain barrier by connecting stem-cell-derived mini-brains with a brain blood vessel.
- The CONNECT research project was led by Elly Hol of UMC Utrecht and Elga de Vries of Amsterdam UMC.
- The model is funded by the Hersenstichting, Stichting Proefdiervrij, NWO, Health~Holland, and the Samenwerkende GezondheidsFondsen (SGF).
The Clinical Challenge of the Blood-Brain Barrier
The human blood-brain barrier serves a vital physiological purpose by shielding the brain against circulating pathogens and toxic substances. However, this dense cellular architecture simultaneously restricts the passage of therapeutic agents, impeding the management of neurological disorders. Investigating how pharmacological candidates can safely cross this barrier has historically involved significant clinical hurdles. Extracting human brain tissue for ex vivo testing carries a high risk of irreversible neurological morbidity, while animal models fail to replicate human vascular and cerebral physiology accurately. These limitations have historically restricted the optimization phase for conditions such as Alzheimer’s disease and Parkinson’s disease.
Engineering the CONNECT Model
To overcome these methodological constraints, investigators developed an innovative dual-system architecture. Researchers cultured human stem cells to form mini-brains and integrated them with a modeled human brain blood vessel. This configuration allows clinical investigators to evaluate precisely which chemical compounds permeate the barrier and observe the subsequent pharmacodynamic effects on adjacent cerebral tissue. According to project leaders Elly Hol, vice dean of research at UMC Utrecht, and Elga de Vries of Amsterdam UMC, the initiative successfully concluded its primary phase with backing from multiple public and private health funds.
“Here, we can in the future better understand how different patients respond to a drug,” explains Elly Hol regarding the next steps for patient-derived stem cell integration.
Future Directions in Individualized Neuropharmacology
With the initial phase of the CONNECT study finalized, the research team aims to refine the model further by utilizing stem cells harvested from individual patients. This personalized methodology seeks to account for inter-individual pharmacokinetic variability, potentially tailoring future neurotherapeutic interventions to specific patient profiles.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*